OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents

[at noodls] – SOUTH SAN FRANCISCO, Calif., March 20, 2013 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that … more

View todays social media effects on OXGN

View the latest stocks trending across Twitter. Click to view dashboard

See who OXiGENE is hiring next, click here to view